Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome

Hospital Universitario de Canarias

Status and phase

Completed

Phase 4

Conditions

Acute Coronary Syndromes

Treatments

Drug: Placebo

Drug: Ivabradine

Study type

Interventional

Funder types

Other

Identifiers

NCT00815100

Riviera/09

Details and patient eligibility

About

The purpose of this study is to investigate whether a pure heart rate-lowering agent (Ivabradine) reduces vascular inflammatory stress in patients with acute coronary syndromes

Full description

The activation of inflammatory pathways plays an important contributory role in coronary plaque instability and subsequent rupture, which can lead to the development of acute coronary syndromes. Elevated levels of serum inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) represent independent risk factors for further cardiovascular events. Raised resting heart rate (HR) has been shown to be associated with cardiovascular events. Ivabradine is a new HR-reducing agent, which has demonstrated antianginal and anti-ischemic properties in patients with stable angina. In an atherosclerosis model, selective HR reduction with ivabradine has been shown to decrease markers of vascular oxidative stress, to improve endothelial function, and to reduce atherosclerotic plaque formation. We hypothesized that the addition of ivabradine to standard medical therapy has a beneficial effect on markers of inflammatory stress in acute coronary syndrome patients.

Enrollment

27 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female.
Age > 18 years.
Ischemic symptoms suspected to represent a non-ST segment elevation acute coronary syndrome defined as:

Clinical history consistent with new onset, or a worsening pattern, of characteristic ischemic chest pain occuring at rest or with minimal exertion (lasting longer than 10 min) and planned to be managed with an early invasive strategy with intention to perform a percutaneous coronary intervention as early as possible and not later than 72 hours of randomization, and at least one of the following:
1. ECG changes compatible with new ischemia (ST depression of at least 1 mm or transient ST elevation or ST elevation of <1 mm or T wave inversion >3 mm in at least 2 contiguous leads; or
2. Already elevated cardiac enzymes (eg, CK-MB) or biomarkers (troponin I or T) above the upper limit of normal.
Patients should be in sinus rhythm with a resting HR of > 60 beats per minute on a resting standard 12-lead ECG.
Written informed consent obtained.

Exclusion criteria

Patients unlikely to cooperate in the study or with inability or unwillingness to give informed consent.
Pregnant or breast-feeding women or women of childbearing potential.
Patients with recent (< 6 months) myocardial infarction or coronary revascularization or with a history of stroke or cerebral transient ischemic attack within the preceding 3 months or scheduled for revascularization (percutaneous coronary intervention and coronary artery bypass graft).
Patients with at least 1 of the following criteria:
- Implanted pacemaker or implantable cardioverter defibrillator.
- Valvular disease likely to require surgery within the next 2 years.
- Sick sinus syndrome, sinoatrial block, congenital long QT syndrome, complete atrioventricular block.
- Expectation of death from other illness during the course of the trial.
- Known severe liver or renal disease.
- Requiring or likely to require the following medications: macrolide antibiotics, cyclosporin, gestodene, antiretroviral drugs or azole antifungals such as ketoconazole or with known hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
Patients with systemic or cardiac inflammatory processes with the exception of atherosclerosis.